[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Generics in Australia - Market Summary, Competitive Analysis and Forecast to 2025

July 2021 | 41 pages | ID: G1D70341D04AEN
MarketLine

US$ 350.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Generics in Australia - Market @Summary, Competitive Analysis and Forecast to 2025

SUMMARY

Generics in Australia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY HIGHLIGHTS
  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Australian generics market had total revenues of $1.3bn in 2020, representing a compound annual growth rate (CAGR) of 3.6% between 2016 and 2020.
  • Market consumption volume increased with a CAGR of 5.5% between 2016 and 2020, to reach a total of 66.8% in 2020.
  • The Australian government has undertaken cost containment measures in the pharmaceuticals market due to the growing and aging population, which has resulted in an increasing demand for generic medicines.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Australia
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Australia
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Australia generics market with five year forecasts
REASONS TO BUY
  • What was the size of the Australia generics market by value in 2020?
  • What will be the size of the Australia generics market in 2025?
  • What factors are affecting the strength of competition in the Australia generics market?
  • How has the market performed over the last five years?
  • What are the main segments that make up Australia's generics market?
1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape

2 MARKET OVERVIEW

2.1. Market definition
2.2. Market analysis

3 MARKET DATA

3.1. Market value
3.2. Market volume

4 MARKET SEGMENTATION

4.1. Geography segmentation

5 MARKET OUTLOOK

5.1. Market value forecast
5.2. Market volume forecast

6 FIVE FORCES ANALYSIS

6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry

7 COMPETITIVE LANDSCAPE

7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the COVID-19 pandemic impacted leading players?

8 COMPANY PROFILES

8.1. Teva Pharmaceutical Industries Limited
8.2. Viatris Inc.
8.3. Aspen Pharmacare Holdings Ltd
8.4. Lupin Ltd

9 MACROECONOMIC INDICATORS

9.1. Country data

10 APPENDIX

10.1. Methodology
10.2. About MarketLine

LIST OF TABLES

Table 1: Australia generics market value: $ million, 2016-20
Table 2: Australia generics market volume: %, 2016-20
Table 3: Australia generics market geography segmentation: $ million, 2020
Table 4: Australia generics market value forecast: $ million, 2020-25
Table 5: Australia generics market volume forecast: %, 2020-25
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Viatris Inc.: key facts
Table 10: Viatris Inc.: Annual Financial Ratios
Table 11: Viatris Inc.: Key Employees
Table 12: Aspen Pharmacare Holdings Ltd: key facts
Table 13: Aspen Pharmacare Holdings Ltd: Annual Financial Ratios
Table 14: Aspen Pharmacare Holdings Ltd: Key Employees
Table 15: Lupin Ltd: key facts
Table 16: Lupin Ltd: Annual Financial Ratios
Table 17: Lupin Ltd: Key Employees
Table 18: Lupin Ltd: Key Employees Continued
Table 19: Australia size of population (million), 2016-20
Table 20: Australia gdp (constant 2005 prices, $ billion), 2016-20
Table 21: Australia gdp (current prices, $ billion), 2016-20
Table 22: Australia inflation, 2016-20
Table 23: Australia consumer price index (absolute), 2016-20
Table 24: Australia exchange rate, 2016-20

LIST OF FIGURES

Figure 1: Australia generics market value: $ million, 2016-20
Figure 2: Australia generics market volume: %, 2016-20
Figure 3: Australia generics market geography segmentation: % share, by value, 2020
Figure 4: Australia generics market value forecast: $ million, 2020-25
Figure 5: Australia generics market volume forecast: %, 2020-25
Figure 6: Forces driving competition in the generics market in Australia, 2020
Figure 7: Drivers of buyer power in the generics market in Australia, 2020
Figure 8: Drivers of supplier power in the generics market in Australia, 2020
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Australia, 2020
Figure 10: Factors influencing the threat of substitutes in the generics market in Australia, 2020
Figure 11: Drivers of degree of rivalry in the generics market in Australia, 2020


More Publications